Haywood Initiates Coverage On Cresco Labs With $14.00 Price Target

Last week, Haywood Securities initiated coverage on Cresco Labs (CSE: CL) with a C$14.00 price target and a buy rating. Although they have their price target of C$14.00, they also give a scenario analysis for Cresco Lab’s share’s to be as low as C$5.50.

Neal Gilmer, Haywood’s cannabis analyst, says, “we believe the company is positioned to demonstrate improving operating leverage in the business,” and that their previous purchase of Origin House “increased its exposure to what is already the worlds largest state cannabis market in California.”

Further, Gilmer comments that despite vertical integration, the company is the largest wholesaler of branded cannabis products, with the company also expanding heavily in terms of capacity in the key states of Illinois and Pennsylvania. Below you can see Cresco Lab’s dispensary license breakdown.

Gilmer says, “We forecast the company to post strong growth over the next few quarters,” due to Cresco Labs having exposure to the very high growth markets that are Illinois, Pennsylvania and California.” Gilmer is forecasting quarter over quarter revenue growth to be 28% for the third quarter which he says, “we believe could be conservative.” The current forecast is expecting revenues of $120.4 million and adjusted EBITDA of $26.4 million for the three month period.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

Onto their fourth-quarter estimates, Haywood is forecasting revenue will grow 21% quarter over quarter. Their full-year 2020 and 2021 revenue estimates are $426.4 million and $748.2 million, respectively. Earnings per share are forecasted to be ($0.07) and then turning positive to $0.25 for 2020 and 2021, respectively.

Finally, Gilmer comments that Cresco Labs has a strong management team with, “extensive experience in the CPG sector,” and believes that this should significantly enable the company to capture market share through its brands.

The current $14.00 price target placed on Cresco Labs assumed a 17x EV/EBITDA multiple for the multi state operator based on 2021 EBITDA estimates, which is then discounted by 5%. Comparatively, the downside case of $5.50 per share uses a multiple of 5x in the same scenario.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Inside a Forgotten High-Grade Gold Mine in the Yukon | Blue Jay Gold [DD-on-the-GO Ep. 10]

WHICH MINING STOCKS CAN STILL RUN? | Mining Stock Mailbag [Nov. 9-13]

Silver’s Bull Market Isn’t Over | Peter Krauth

Recommended

Epic Gold Delivers Maiden 279,000 Ounce Inferred Resource at Wilson Project

First Phosphate Adds UK Export Finance to Growing Export Credit Lineup With C$220 Million Letter of Interest

Related News

K92 Mining: BMO Reiterates Ratings After 2022 Guidance Release

On January 24th, K92 Mining Inc. (TSX: KNT) announced their 2022 operational guidance, wherein the...

Sunday, January 30, 2022, 01:12:00 PM

Valens: Canaccord Cuts Price Target To $4.00 Due To Tapered Growth

On July 13, The Valens Company Inc. (TSX: VLNS) reported its second quarter financial results...

Tuesday, July 19, 2022, 04:56:00 PM

Twitter: Analysts Call For $1.31 Billion In Q2 Revenue

Twitter (NYSE: TWTR) will be reporting its second quarter financial results on July 22 before...

Thursday, July 21, 2022, 05:07:00 PM

PI Financial: US Cannabis Has “Good Growth Prospects”

On Tuesday, PI Financial released their fourth quarter 2021 earnings review on their cannabis sector....

Thursday, April 21, 2022, 02:21:00 PM

Cresco Labs to Sell Illinois Properties in Leaseback Arrangement

Cresco Labs (CSE: CL) announced this morning that it would be entering a sale and...

Friday, September 27, 2019, 09:07:51 AM